fermer

Pharmacokinetics and tolerability of ABX464, a novel first-in-class compound to treat HIV infection, in healthy HIV-uninfected subjects.

Scherrer D, Rouzier R, Noel Barrett P, Steens JM, Gineste P, Murphy RL, Tazi J, Ehrlich HJ.

J Antimicrob Chemother

2017 Mar 1 / vol 72(3) / pages 820-828

Abstract

Full Text Free

Lire sur PubMed

10.1093/jac/dkw458.

IGMM team(s) involved in this publication

Toutes les publications